<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707144</url>
  </required_header>
  <id_info>
    <org_study_id>ALR_2020_40</org_study_id>
    <nct_id>NCT04707144</nct_id>
  </id_info>
  <brief_title>Performance Evaluation of a 3D PSIR Sequence in MRI at 1.5T in the Detection and Characterization of Spinal Cord Injuries in Patients With Multiple Sclerosis</brief_title>
  <acronym>ESPOIR 1-5</acronym>
  <official_title>Performance Evaluation of a 3D PSIR Sequence in MRI at 1.5T in the Detection and Characterization of Spinal Cord Injuries in Patients With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inclusion visit (D0):&#xD;
&#xD;
        -  verification of inclusion and non-inclusion criteria&#xD;
&#xD;
        -  information and collection of consent&#xD;
&#xD;
        -  standard imaging protocol prescribed as part of the usual treatment: sagittal T1 and T2&#xD;
           slices after injection of contrast product (Gadolinium), o 3D STIR sequence.&#xD;
&#xD;
        -  3D PSIR sequence at the level of the cervical cord for the duration of the additional&#xD;
           sequence is 10 minutes, for a total examination time of 45 minutes (instead of 35&#xD;
           minutes).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the number of spinal cord injuries detected with the set of standard sequences (T1, T2 and STIR) that are not detected with the 3D PSIR sequence</measure>
    <time_frame>1 DAY</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate the number of active lesions taking the contrast after injection of gadolinium, with the 3D PSIR sequence which is not detected in the set of standard sequences (T1, T2 and STIR)</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the diagnostic confidence expressed by the radiologist for the detection of spinal cord injuries with the 3D PSIR sequence compared to the set of standard sequences (T1, T2 and STIR)</measure>
    <time_frame>1 DAY</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe the quality of the images in terms of artifacts for each of the sequences used (T1, T2, STIR and PSIR)</measure>
    <time_frame>1 DAY</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the signal-to-noise ratio of each of the sequences used (T1, T2, STIR and PSIR)</measure>
    <time_frame>1 DAY</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the inter-observer agreement on the number of lesions detected with the 3D PSIR sequence</measure>
    <time_frame>1 DAY</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the intra-observer agreement on the number of lesions detected with the 3D PSIR sequence</measure>
    <time_frame>1 DAY</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Multiple Sclerosis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI 1.5 tesla</intervention_name>
    <description>standard imaging protocol prescribed as part of the usual treatment: sagittal T1 and T2 slices after injection of contrast product (Gadolinium), o 3D STIR sequence.&#xD;
3D PSIR sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 45 minutes (instead of 35 minutes)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study will be offered prospectively to patients presenting to the imaging department&#xD;
        for a 1.5T MRI for bone marrow exploration, in the context of inflammatory involvement of&#xD;
        the nevrax&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 18 years old&#xD;
&#xD;
          -  To benefit from a medullary exploration planned by MRI 1.5T as part of a first&#xD;
             evaluation or a re-evaluation of inflammatory involvement of the nevrax&#xD;
&#xD;
          -  Express consent to participate in the study&#xD;
&#xD;
          -  Affiliate or beneficiary of a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient benefiting from a legal protection measure&#xD;
&#xD;
          -  Pregnant, parturient or breastfeeding woman&#xD;
&#xD;
          -  Absolute or relative contraindication to MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>amélie YAVCHITZ</last_name>
    <phone>0148036454</phone>
    <email>ayavchitz@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>AUGUSTIN LECLER</last_name>
    <phone>0148036401</phone>
    <email>alecler@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU DE Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benoit DOCHE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Clermont-Ferrand</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sonia MIRAFZAL</last_name>
      <email>sonia_mirafzal@hotmail.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier OUTTERYCK</last_name>
      <email>Olivier.OUTTERYCK@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de LYON</name>
      <address>
        <city>Lyon</city>
        <zip>69002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François COTTON</last_name>
      <email>francois.cotton@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital privé des Peupliers</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julien SAVATOVSKY</last_name>
      <email>jsavatovsky@for.paris</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Adolphe de Rothschild (FOR)</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amélie YAVCHITZ</last_name>
      <phone>0148036431</phone>
      <email>ayavchitz@for.paris</email>
    </contact>
    <investigator>
      <last_name>Augustin LECLER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

